Guinness Atkinson Files ETF Targeting AI-Driven Drug Discovery

The Guinness Atkinson AI Drug Discovery ETF (RXAI) will track track an index of companies using artificial intelligence and machine learning to accelerate drug discovery and development. The index includes biotechnology and pharmaceutical companies applying AI to identify drug targets, design molecules, and improve clinical development, alongside technology firms providing the computing, software, data, and laboratory infrastructure that support AI-driven research. The ETF will invest globally, including in developed and emerging markets, and will concentrate its holdings in the pharmaceutical, biotechnology, and life sciences industries.